These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11862257)

  • 1. Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: A Case Presentation and Review of the Literature.
    Samaniego-Picota MD; Whelton A
    Am J Ther; 1996 Mar; 3(3):248-257. PubMed ID: 11862257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglycoside nephrotoxicity: keys to prevention.
    Levin ML
    J Crit Illn; 1994 Oct; 9(10):911-2, 915. PubMed ID: 10150695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
    Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
    J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin-induced renal insufficiency in cystic fibrosis.
    Moffett BS; Rosenstein BJ; Mogayzel PJ
    J Cyst Fibros; 2003 Sep; 2(3):152-4. PubMed ID: 15463865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.
    Destache CJ
    J Pharm Pract; 2014 Dec; 27(6):562-6. PubMed ID: 25124375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is it possible to reduce the incidence of aminoglycoside-induced nephrotoxicity?].
    Fillastre JP
    Bull Acad Natl Med; 1999; 183(5):973-82; discussion 983. PubMed ID: 10465001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control study of acute renal failure in patients with cystic fibrosis in the UK.
    Smyth A; Lewis S; Bertenshaw C; Choonara I; McGaw J; Watson A
    Thorax; 2008 Jun; 63(6):532-5. PubMed ID: 18245146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular nephrotoxicity of aminoglycosides.
    Martínez-Salgado C; López-Hernández FJ; López-Novoa JM
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):86-98. PubMed ID: 17602717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
    Beringer PM; Kriengkauykiat J; Zhang X; Hidayat L; Liu S; Louie S; Synold T; Burckart GJ; Rao PA; Shapiro B; Gill M
    Pharmacotherapy; 2008 Jul; 28(7):883-94. PubMed ID: 18576903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-induced vestibular injury: maintaining a sense of balance.
    Ariano RE; Zelenitsky SA; Kassum DA
    Ann Pharmacother; 2008 Sep; 42(9):1282-9. PubMed ID: 18648019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
    Graham AC; Mercier RC; Achusim LE; Pai MP
    Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and risk factors of colistin-induced nephrotoxicity.
    Kim J; Lee KH; Yoo S; Pai H
    Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
    Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
    J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.